News

NICE proposes to withdraw Alzheimer's drugs from NHS

BMJ 2005; 330 doi: 10.1136/bmj.330.7490.495-a (Published 3 March 2005)
Cite this as: BMJ 2005;330:495.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Zosia Kmietowicz
  1. London

    The drugs donepezil, rivastigmine, galantamine, and memantine should no longer be prescribed on the NHS to treat Alzheimer's disease, says new draft guidance from the National Institute for Clinical Excellence (NICE).

    NICE, the NHS prescribing watchdog for England and Wales, has retracted its previous guidance“issued in 2001 and which said that these drugs should be prescribed for Alzheimer's disease—after reviewing the latest evidence on efficacy and cost effectiveness. Patients currently receiving any of the drugs, however, can continue to do so. Memantine will be available only as part of …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular